Bioasis Technologies Inc. V.BTI

RE:Collaboration with Jansen

[KayakerBC]

Acquisition opportunities scare me at this point in the game given that Bioasis has not yet accomplished anything truly worthy of a sp increase.

I'll repeat what I've said before.  If an "acquisition" is a Contingent Value Rights (CVR) deal, I'll consider it a disaster and will most definitely vote against it.

Shadowy Shares: The Dark Side of Contingent Value Rights
Forbes

"Companies and private equity funds shopping for U.S. biotechnology and pharmaceutical corporations have discovered a neat way to lubricate deals in a volatile market: place all the risk associated with the acquisition on the backs of investors in their target corporation...."

And there have been lawsuits from shareholders alleging delayed time frames and avoidance of payments.

Bristol Myers will likely settle the $6.4B Celgene CVR lawsuit at a discount, analyst says. Here's why.
Fierce Pharma

"....In the Sanofi CVR suit, plaintiffs alleged that the French pharma failed to do its best in getting a timely approval for Lemtrada and achieving certain sales milestones. By doing so, the company dodged its CVR payment obligations of $708 million, they alleged...."